Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

(2015) D A Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus

(2015) D C Salazar-Camarena et al.   LUPUS

Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Pilot Trial

(2015) R. F. van Vollenhoven et al.   Arthritis & Rheumatology

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

(2014) R A Furie et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

(2014) David Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL

(2014) M. J. Benson et al.   JOURNAL OF IMMUNOLOGY

Systemic lupus erythematosus

(2014) Larissa Lisnevskaia et al.   LANCET

The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved

(2014) Ole Petter Rekvig et al.   Seminars in Immunopathology

Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus

(2013) A. Schmeding et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort

(2013) E. M. McCarthy et al.   RHEUMATOLOGY

The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey

(2013) C. Gordon et al.   RHEUMATOLOGY

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Unmet medical needs in systemic lupus erythematosus

(2012) Aisha Lateef et al.   ARTHRITIS RESEARCH & THERAPY

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial

(2011) R. F. van Vollenhoven et al.   ARTHRITIS AND RHEUMATISM

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Raised serum level of APRIL in patients with systemic lupus erythematosus: Correlations with disease activity indices

(2010) M. Hegazy et al.   CLINICAL IMMUNOLOGY

Regulation of the B Cell Receptor Repertoire and Self-Reactivity by BAFF

(2010) M. Ota et al.   JOURNAL OF IMMUNOLOGY

Prednisone, Lupus Activity, and Permanent Organ Damage

(2009) M. THAMER et al.   JOURNAL OF RHEUMATOLOGY

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

(2009) C Pena-Rossi et al.   LUPUS

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

(2008) E. Belnoue et al.   BLOOD